New Beyfortus data featured at IDWeek reinforce real-world effectiveness against RSV disease and hospitalization in infants Paris, . Sanofi advances its ambition to protect ...
John Sundy is currently Chief Medical Officer and Head of Research and Development at Seicmic Therapeutic, a machine learning immunology company and is Adjunct Professor of Medicine in the Division of ...
Sanofi’s commitment to society is long-term, and a longstanding legacy. Our commitment translates into a set of actions to make a positive impact on the lives of people and communities around the ...
Dupixent approved in the US as the first-ever biologic medicine for patients with COPD Dupixent is indicated for the approximately 300,000 adults in the US with inadequately ...
Press Release: Dupixent approved in China as the first-ever biologic medicine for patients with COPD
Dupixent approved in China as the first-ever biologic medicine for patients with COPD Approval follows EU approval of Dupixent for adults with COPD with raised blood eosinophils, and is based on ...
EADV: New data reinforce Sanofi’s innovative approach and leadership across immune-mediated skin diseases 24 abstracts for Dupixent, including 4 oral presentations, highlight impact of ...
100% of developing countries work towards the UNFCCC goal of having their NAPs in place by 2025, with all new NAPs including specific health targets reflecting national and sub-national priorities.
100 % des pays en développement œuvrent pour atteindre l'objectif de la CCNUCC d'avoir leurs PNA (Plans nationaux d'adaptation) en place d'ici 2025, avec l'inclusion dans chaque nouveau PNA ...
Parfois, l’innovation technologique peut provenir d’espace inattendus. Dans le développement de médicaments, cela signifie souvent l’intersection de technologies apparemment sans rapport ou de ...
Sometimes transformative technology comes from unexpected places. In drug development, that often means the intersection of seemingly unrelated technologies or esoteric areas of science. French ...
Les résultats du troisième trimestre 2024 seront commentés par le management au cours d'un webcast audio en direct avec la communauté financière. La présentation sera suivie d'une session de questions ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback